Small cell lung cancertreatmentradiationchemotherapySmall-cell lung cancer (SCLC) accounts for 13-20#x0025; of all lung cancers. Stongly associated with smoking and initially responsive to treatment, it results in death within 2-4 months without treatment. Limited-stage disease is treated with ...
Treatment of Small Cell Lung Cancer in the ElderlySCLCElderlySmall cell lung cancer (SCLC) accounts for approximately 20% of lung carcinomas. Chemotherapy is the cornerstone of treatment for SCLC. In limited disease, the median survival time is about 12-16 months, with a 4%-5% long-term ...
The present invention provides a small cell lung cancer therapeutic agent or a small cell lung cancer cell growth inhibitor comprising the peptide of any one of SEQ ID NOs: 1 to 5.收藏 引用 批量引用 报错 分享 全部来源 求助全文 掌桥科研 相似文献...
Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy Clinical development of immune checkpoint blockade has dramatically changed the treatment paradigm and prognosis for patients with non-small cell lung canc... Patel,A Shetal,Weiss,... 被引量: 0发表: 0年 Crizotinib for the ...
Small cell lung cancer (SCLC) is a difficult to treat subtype of lung cancer. One of the hallmarks of SCLC is its almost uniform chemotherapy sensitivity. However, chemotherapy response is typically transient and patients frequently succumb to SCLC withi
Two main lung cancer types exist small-cell lung cancer (SCLC, or small cell lung carcinoma, also formerly called oat cell cancer) and non-small-cell lung cancer (NSCLC). Most lung cancers are NSCLC, including squamous cell carcinoma and adenocarcinoma of the lung. Small-cell lung cancer ...
small cell lung cancer; treatment Abstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in the world. ...
? 2022 Elsevier B.V.Small cell lung cancer (SCLC) is a deadly disease with poor prognosis. Fast growing speed, inclination to metastasis, enrichment in cancer stem cells altogether constitute its aggressive nature. In stark contrast to non-small cell lung cancer (NSCLC) that strides vigorously ...
Carboplatin in the Treatment of Small Cell Lung Cancer Small cell lung cancer (SCLC) will account for approximately 20%-25% of the 171,500 estimated new lung cancer cases in 1998. Combination cytotoxic therapie... JR Brahmer,DS Ettinger - 《Lung Cancer》 被引量: 52发表: 1998年 Radiosensiti...
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US...